CRISPR Therapeutics AG (CRSP) currently has a stock price of $53.62. The stock saw a sharp increase in the last trading session, hitting a high of $268.0 after opening at $54.24. The lowest recorded price for the day was $32.0 before it closed at $52.73.
In terms of market performance, CRISPR Therapeutics AG had a somewhat regular. The highest value for the stock in the past year was $63.68 on 07/17/24, while the lowest value was $30.04 on 04/07/25.
52-week price history of CRSP Stock
A stock’s 52-week high and low prices can reveal a great deal about its present condition and potential future performance. CRISPR Therapeutics AG’s current trading price is -15.79% away from its 52-week high, while its distance from the 52-week low is 78.51%. The stock’s price range during this period has fluctuated between $30.04 and $63.68. Shares of the company, which operates in the Healthcare sector, recorded a trading volume of around 2.11 million for the day, which was evidently lower than the average daily volume of 2.65 million over the last three months.
Financial Performance and Market Capitalization
CRISPR Therapeutics AG (CRSP) has experienced a quarterly rise of 38.17% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 4.63B and boasts a workforce of 393 employees.
Analysts’ Ratings For CRISPR Therapeutics AG
As of right now, 12 analysts are rating CRISPR Therapeutics AG as a BUY, 5 of the polled analysts branded the stock as an OVERWEIGHT, 10 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 analyst is rating the stock as SELL.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 41.39, with a change in price of +3.71. Similarly, CRISPR Therapeutics AG recorded 2,437,935 in trading volume during the last 100 days, posting a change of +7.36%.
CRSP Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CRSP stands at 0.12. Similarly, the long-term debt-to-equity ratio is also 0.11.
CRSP Stock Stochastic Average
The raw stochastic average for CRISPR Therapeutics AG over the last 50 days is presently at 72.87%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 60.36%. Further, the company’s Stochastic %K and %D values for the last 20 days were 63.79% and 70.73%, respectively.
CRSP Stock Price Performance Analysis
The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -7.38%.However, over the last six months, we can see a weaker performance of 38.03%. Over the last 30 days, the price of CRSP has fallen by 29.65%. And in the last five days, it has fallen by -10.74%.
